OncoNano Presents Compelling Data for ONM-501 and a Novel Tumor Specific Delivery Technology at AACR…
Amy MartinezApril 18, 2023
OncoNano Medicine Presents Data from Phase 2 Pegsitacianine Study at Society of Surgical Oncology (SSO)…
Amy MartinezMarch 27, 2023
Southlake, TX – January 4, 2023 – OncoNano Medicine, Inc. today announced three poster presentations at…
Amy MartinezMarch 16, 2023
Southlake, TX – January 4, 2023 – OncoNano Medicine, Inc. today announced that its lead clinical…
Amy MartinezJanuary 4, 2023
Clinically validated pH-sensitive nanomedicine platform allows for tumor specific delivery of protein therapeutics and increased…
Amy MartinezNovember 14, 2022
ONM-501 shown to be promising immuno-therapeutic candidate for clinical evaluation in solid tumors SOUTHLAKE, Texas…
Amy MartinezNovember 14, 2022
